Streetbeat News

Equity Actions

NNDM

Nano Dimension (NYSE:NNDM) has seen a decrease in short interest, with the current short percent of float at 5.82%, representing 13.54 million shares. The short interest has fallen by 8.49% since the last report, and it would take about 7.78 days for traders to cover their short positions based on average trading volume. This decline in short interest may indicate a more bullish sentiment among investors, although it does not necessarily predict a near-term rise in stock price. Nano Dimension's short interest is below its peer group average of 6.86%.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:15 pm

BNRG

Brenmiller Energy Ltd. (NASDAQ:BNRG) has priced a $4M offering with a U.S. based institutional investor, selling 888,890 units at $4.50 each. Each unit includes one ordinary share or pre-funded warrant and one warrant to purchase an additional share at $5.00. The offering is expected to close on January 25, 2024, with proceeds intended for corporate purposes, working capital, and capital expenditures. A.G.P./Alliance Global Partners is the sole placement agent.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:15 pm

OTLK

Outlook Therapeutics has announced a private placement deal worth up to $172 million to fund the advancement of ONS-5010. The deal includes up to $65 million in common stock and up to $107 million from the cash exercise of warrants, contingent on closing conditions. This capital raise involves top tier institutional investors and insiders.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:05 pm

INO

INOVIO Pharmaceuticals has announced a 1-for-12 reverse stock split, set to take effect on January 24, 2024. This action is typically taken by companies to boost the share price to meet exchange listing requirements or to improve perceptions of the stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:02 pm

SLDP

Solid Power, a company specializing in solid-state batteries, has announced a share repurchase program authorizing the buyback of up to $50 million of its shares. This move reflects the company's confidence in its financial stability and future prospects. Share repurchase programs are often seen as a positive signal to the market, indicating that the company believes its shares are undervalued and that it has sufficient cash reserves to return value to shareholders.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:01 pm

NARI

Inari Medical (NASDAQ:NARI) has received mixed analyst ratings over the past three months, with 4 analysts offering diverse perspectives. The average 12-month price target for NARI is $73.00, with a high estimate of $85.00 and a low of $65.00, marking a slight increase from the previous target of $71.67. Analysts from Needham, Truist Securities, and Piper Sandler have adjusted their ratings and price targets, reflecting their latest views on the company's performance. Inari Medical, a medical device company, has shown strong financial performance with a revenue growth of 31.35%, a net margin of 2.5%, and an ROE of 0.71%. The company's market capitalization is below industry averages, but it has a low debt-to-equity ratio of 0.07.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:01 pm

MU

Micron Technology (NASDAQ:MU) has been evaluated by 33 analysts over the last three months, with a diverse range of opinions. The recent ratings show a shift towards a more bullish sentiment, with no bearish ratings in the last 30 days. Analysts have raised their 12-month price targets for MU, with an average target of $94.46, reflecting a 13.71% increase from the previous average of $83.07. The article also provides a detailed breakdown of individual analyst actions and their revised price targets. Micron's financial performance shows solid revenue growth but below industry benchmarks in net margin, ROE, and ROA, with a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:01 pm

SAFE

Safehold Inc. (NYSE:SAFE) has received mixed analyst ratings over the past three months, with 7 analysts offering a range of opinions. The average 12-month price target for SAFE is $28.14, representing an 11.67% increase from the previous target of $25.20. Analysts from firms including JMP Securities, Goldman Sachs, Jefferies, JP Morgan, Truist Securities, and RBC Capital have adjusted their ratings and price targets. Safehold's financial health indicators show positive revenue growth but below-average ROE and ROA, with a debt-to-equity ratio below the industry average.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:00 pm

DXCM

Over the past three months, 6 analysts have provided ratings for DexCom (NASDAQ:DXCM), with recent updates showing a positive trend in sentiment and an increase in the 12-month price target to an average of $134.5, up from $120.33. Analysts from firms such as Raymond James, Piper Sandler, Wells Fargo, and Morgan Stanley have raised their price targets, reflecting optimism about DexCom's financial health, which includes strong revenue growth, net margin, ROE, and ROA, despite some concerns over debt management.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:00 pm

GFS

Analysts have varying opinions on GLOBALFOUNDRIES (NASDAQ:GFS), with recent ratings ranging from bullish to bearish. Over the last quarter, there were 4 somewhat bullish and 1 indifferent rating. The average 12-month price target is now $68.6, down from $75.00, with a high estimate of $75.00 and a low of $65.00. Analysts from firms like Cantor Fitzgerald, B of A Securities, Morgan Stanley, JP Morgan, and Susquehanna have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. GLOBALFOUNDRIES, a semiconductor manufacturer, faces challenges with a -10.7% revenue decline, below-average net margin, ROE, and ROA, but has a conservative debt-to-equity ratio of 0.25.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 12:01 pm